Multiparametric ECIS Profiling Complements Metabolic Endpoint Screening of Complex Plant Extracts in HNSCC Models.
- 1Department of Oral, Maxillofacial and Plastic Surgery, Rostock University Medical Center, Schillingallee 35, 18057 Rostock, Germany.
- 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Benin, Ugbowo, Benin City 300001, Nigeria.
- 3Oscar Langendorff Institute of Physiology, Rostock University Medical Center, Gertrudenstrasse 9, 18057 Rostock, Germany.
Abstract
Metabolic endpoint assays enable rapid screening but provide limited information on treatment kinetics, heterogeneity, and recovery. Here, we established a multistep workflow combining MTS-based metabolic screening with electric cell-substrate impedance sensing (ECIS), a label-free cell-based biosensor, to functionally prioritize complex plant extracts in head and neck squamous cell carcinoma (HNSCC) models. Seventeen soluble extracts were screened at 50 µg/mL for 24 h in four HNSCC cell lines and human adipose-derived stem cells. Selected candidates were characterized by real-time impedance monitoring, multifrequency analysis, and model-derived barrier resistance. Extract 16 showed the most favorable metabolic selectivity profile. ECIS resolved no growth-inhibitory effects, sustained impedance suppression, heterogeneous responses, and transient suppression followed by partial recovery. Recovery was incomplete (CAL-33) or absent (Detroit 562); modeled barrier resistance became resolvable late (FaDu, PE/CA-PJ15) or not at all (CAL-33). Comparison with the PI3Kα inhibitor Inavolisib revealed partially overlapping but non-identical metabolic response profiles and no consistent enhancement by combination treatment. Extract 16 was associated with junctional redistribution, F-actin remodeling, and cell line-dependent PARP cleavage, whereas caspase 3/7 activation could not be detected. Integrating metabolic endpoint screening with multiparametric ECIS monitoring provides greater functional resolution and supports prioritizing complex bioactive samples for chemical and mechanistic investigation.
Related
- LLM-assisted evidence audit of late-stage cancer incidence as a screening trial endpoint
- Specialist-led community-based cardio-kidney-metabolic-pulmonary care in high-risk individuals: multi-centre pragmatic prospective randomized open-label blinded endpoint trial.
- Metabolic profiling reveals heterogeneity within childhood obesity phenotypes
- Blood Cytokine Profiling Reveals Distinct Inflammatory Signatures in Phenotypes A and B of Polyendocrine Metabolic Ovarian Syndrome (PMOS; formerly PCOS).
- An automated ranking platform for machine learning regression models for meat spoilage prediction using multi-spectral imaging and metabolic profiling
BibTeX
@article{handrick2026multiparametric,
title = {{Multiparametric ECIS Profiling Complements Metabolic Endpoint Screening of Complex Plant Extracts in HNSCC Models.}},
author = {Fine Handrick and Vincent O Imieje and Vivien Engel and Esther Abiodun Odigie and Ewelukwa Ebube Chukwueloka and Lilian Nneoma Amafili and Onome Keturah Evi and Nadja Engel},
journal = {Biosensors},
year = {2026},
month = oct,
doi = {10.3390/bios16100563},
url = {https://europepmc.org/article/MED/42930110},
note = {CC BY},
}
RIS
TY - JOUR
TI - Multiparametric ECIS Profiling Complements Metabolic Endpoint Screening of Complex Plant Extracts in HNSCC Models.
AU - Fine Handrick
AU - Vincent O Imieje
AU - Vivien Engel
AU - Esther Abiodun Odigie
AU - Ewelukwa Ebube Chukwueloka
AU - Lilian Nneoma Amafili
AU - Onome Keturah Evi
AU - Nadja Engel
PY - 2026
DA - 2026/10/05
JO - Biosensors
DO - 10.3390/bios16100563
UR - https://europepmc.org/article/MED/42930110
AB - Metabolic endpoint assays enable rapid screening but provide limited information on treatment kinetics, heterogeneity, and recovery. Here, we established a multistep workflow combining MTS-based metabolic screening with electric cell-substrate impedance sensing (ECIS), a label-free cell-based biosensor, to functionally prioritize complex plant extracts in head and neck squamous cell carcinoma (HNSCC) models. Seventeen soluble extracts were screened at 50 µg/mL for 24 h in four HNSCC cell lines and human adipose-derived stem cells. Selected candidates were characterized by real-time impedance monitoring, multifrequency analysis, and model-derived barrier resistance. Extract 16 showed the most favorable metabolic selectivity profile. ECIS resolved no growth-inhibitory effects, sustained impedance suppression, heterogeneous responses, and transient suppression followed by partial recovery. Recovery was incomplete (CAL-33) or absent (Detroit 562); modeled barrier resistance became resolvable late (FaDu, PE/CA-PJ15) or not at all (CAL-33). Comparison with the PI3Kα inhibitor Inavolisib revealed partially overlapping but non-identical metabolic response profiles and no consistent enhancement by combination treatment. Extract 16 was associated with junctional redistribution, F-actin remodeling, and cell line-dependent PARP cleavage, whereas caspase 3/7 activation could not be detected. Integrating metabolic endpoint screening with multiparametric ECIS monitoring provides greater functional resolution and supports prioritizing complex bioactive samples for chemical and mechanistic investigation.
SN - 2079-6374
ER -